Supernus Pharma Revenue, Profits - SUPN Quarterly Income Statement

Add to My Stocks
$58.05 $2.85 (5.16%) SUPN stock closing price Jun 20, 2018 (Closing)

Financial analysis of Supernus Pharma involves more than just checking the Supernus Pharma stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the SUPN stock is bound to reflect the impact of the QOQ growth of 2.25%. One also needs to look at Supernus Pharma assets, operating expenses and Supernus Pharma free cash flow. The Supernus Pharma profit and loss statement shows revenue of $90.43M for 2018 Q1. Revenue has grown by 2.25% QoQ for SUPN stock.

View and download details of revenue and profits for Supernus Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Supernus Pharma Revenues or Net Sales
90.43M88.44M80.4M75.83M57.58M62.37M56.81M50.42M43.08M42.66M
Cost Of Goods Sold (COGS)3.27M4.16M4.25M3.86M2.94M3.78M3.42M2.75M2.03M2.81M
Supernus Pharma Gross Profit
87.15M84.3M76.14M71.96M54.62M60.92M53.38M47.67M41.04M39.87M
Research & Development Expense18.9M16.17M12.98M10.82M9.6M13.27M7.86M11.1M10.56M9.46M
Selling General & Admin Expense36.84M33.78M40.82M35.07M28.23M29.06M25.67M26.12M25.16M23.57M
Income Before Depreciation Depletion Amortization31.39M34.36M22.34M26.06M16.78M18.63M19.83M10.44M5.31M6.87M
Depreciation Depletion Amortization----------
Non Operating Income1.2M---------
Interest Expense1.41M---1.04M3.53M1.2M---
Supernus Pharma Pretax Income
31.18M35.06M22.91M26.42M16.22M15.32M19.13M10.73M5.18M7.06M
Provision for Income Taxes4.83M21.42M6.94M9.05M5.92M--42.69M---
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations26.35M13.66M15.96M17.37M10.3M14.32M61.83M10.02M4.99M6.87M
Extraordinary Items & Discontinued Operations----------
Supernus Pharma Profit/ Loss (Net Income)
26.35M13.66M15.96M17.37M10.3M14.32M61.83M10.02M4.99M6.87M
Average Shares used to compute Diluted EPS53.79M53.53M53.63M53.22M52.76M52.02M51.97M51.75M51.15M49.6M
Average Shares used to compute Basic EPS51.54M51.27M51.05M50.53M50.16M49.7M49.52M49.43M49.24M48.89M
Income Before Nonrecurring Items26.35M23.35M15.96M17.37M10.3M14.32M19.53M10.02M4.99M6.87M
Income from Nonrecurring Items--9.69M----42.3M---
Supernus Pharma Earnings Per Share Basic Net
0.510.270.310.340.210.291.250.200.100.14
Supernus Pharma Earnings Per Share Diluted Net
0.490.260.290.320.190.261.180.180.080.14
EPS Diluted Before Nonrecurring Items0.490.440.290.320.190.260.370.180.080.14
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Supernus Pharma stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Supernus Pharma revenue chart, implies that the company is growing. It has been the case with Supernus Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: Most businesses like Supernus Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The SUPN financials along with Supernus Pharma historical stock prices provide a lot of details about the firm.

Supernus Pharma Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
42.68
PS Ratio (price sales ratio)
8.93
Operating Margin
34.7
Net Profit Margin
29.1
Dividend Yield
0%

Other Income Statements - Supernus Pharmaceuticals Inc Industry Peers

Akorn income statement, AxoGen income statement, Catalent income statement, Dr. Reddy's Laboratories income statement